ASRT Stock Summary and Trading Ideas (Assertio Holdings | NASDAQ:ASRT)

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Assertio Holdings trades on the NASDAQ stock market under the symbol ASRT.

As of January 20, 2026, ASRT stock price climbed to $11.69 with 88,783 million shares trading.

ASRT has a beta of 0.95, meaning it tends to be less sensitive to market movements. ASRT has a correlation of 0.13 to the broad based SPY ETF.

ASRT has a market cap of $75.01 million. This is considered a Micro Cap stock.

Last quarter Assertio Holdings reported $49 million in Revenue and $2.70 earnings per share. This beat revenue expectation by $22 million and exceeded earnings estimates by $3.15.

In the last 3 years, ASRT traded as high as $120.15 and as low as $7.71.

The top ETF exchange traded funds that ASRT belongs to (by Net Assets): VTI, VXF, BSVO, RFLR.

ASRT has underperformed the market in the last year with a return of -3.1%, while the SPY ETF gained +15.8%. In the last 3 month period, ASRT fell short of the market, returning -5.4%, while SPY returned +2.9%. However, in the most recent 2 weeks ASRT has outperformed the stock market by returning +27.9%, while SPY returned -0.8%.

ASRT support price is $10.89 and resistance is $12.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASRT shares will trade within this expected range on the day.